Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity

Biological Psychiatry

Volumn 73, Issue 5, 2013, Pages 464-471

  McCormick, Allyson V ^a   Wheeler, Jeanna M ^a   Guthrie, Chris R ^a   Liachko, Nicole F ^a   Kraemer, Brian C ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; antipsychotics; dopamine; drug screen; protein aggregation; tau

Indexed keywords

AMISULPRIDE; AZAPERONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPENTIXOL; HALOPERIDOL; PERPHENAZINE; RISPERIDONE; TAU PROTEIN; TRIFLUOPERAZINE; ZOTEPINE;

ARTICLE; CAENORHABDITIS ELEGANS; CELL STRAIN HEK293; DRUG MECHANISM; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KNOCKOUT GENE; LOCOMOTION; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; RNA INTERFERENCE; TAUOPATHY; TRANSGENE; TRANSGENIC ORGANISM;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BEHAVIOR, ANIMAL; CAENORHABDITIS ELEGANS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; NERVE DEGENERATION; NEUROTOXICITY SYNDROMES; RECEPTORS, DOPAMINE D2; TAU PROTEINS; TAUOPATHIES;

EID: 84873640196     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2012.08.027     Document Type: Article

References (24)

1. E.M. Sigurdsson Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies J Alzheimers Dis 15 2008 157 168
2. B.C. Kraemer, B. Zhang, J.B. Leverenz, J.H. Thomas, J.Q. Trojanowski, and G.D. Schellenberg Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy Proc Natl Acad Sci U S A 100 2003 9980 9985
3. C.R. Guthrie, and B.C. Kraemer Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes J Mol Neurosci 45 2011 32 41
4. G. Shaw, S. Morse, M. Ararat, and F.L. Graham Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells FASEB J 16 2002 869 871
5. C.R. Guthrie, G.D. Schellenberg, and B.C. Kraemer SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans Hum Mol Genet 18 2009 1825 1838
6. M.J. Gravato-Nobre, and J. Hodgkin The acyltransferase gene bus-1 exhibits conserved and specific expression in nematode rectal cells and reveals pathogen-induced cell swelling Dev Dyn 237 2008 3762 3776
7. F.A. Partridge, A.W. Tearle, M.J. Gravato-Nobre, W.R. Schafer, and J. Hodgkin The C. elegans glycosyltransferase BUS-8 has two distinct and essential roles in epidermal morphogenesis Dev Biol 317 2008 549 559
8. L. Buee, L. Troquier, S. Burnouf, K. Belarbi, A. Van der Jeugd, and T. Ahmed From tau phosphorylation to tau aggregation: What about neuronal death? Biochem Soc Trans 38 2010 967 972
9. B.C. Kraemer, and G.D. Schellenberg SUT-1 enables tau-induced neurotoxicity in C. elegans Hum Mol Genet 16 2007 1959 1971
10. X. Huang, H.J. Cheng, M. Tessier-Lavigne, and Y. Jin MAX-1, a novel PH/MyTH4/FERM domain cytoplasmic protein implicated in netrin-mediated axon repulsion Neuron 34 2002 563 576
11. J.M. Beaulieu, and R.R. Gainetdinov The physiology, signaling, and pharmacology of dopamine receptors Pharmacol Rev 63 2011 182 217
12. D.L. Chase, J.S. Pepper, and M.R. Koelle Mechanism of extrasynaptic dopamine signaling in Caenorhabditis elegans Nat Neurosci 7 2004 1096 1103
13. K.Y. Little, L.W. Elmer, H. Zhong, J.O. Scheys, and L. Zhang Cocaine induction of dopamine transporter trafficking to the plasma membrane Mol Pharmacol 61 2002 436 445
14. B. Bulic, M. Pickhardt, E.M. Mandelkow, and E. Mandelkow Tau protein and tau aggregation inhibitors Neuropharmacology 59 2010 276 289
15. Z. Nagy, M.M. Esiri, K.A. Jobst, J.H. Morris, E.M. King, and B. McDonald Relative roles of plaques and tangles in the dementia of Alzheimer's disease: Correlations using three sets of neuropathological criteria Dementia 6 1995 21 31
16. P.V. Arriagada, J.H. Growdon, E.T. Hedley-Whyte, and B.T. Hyman Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease Neurology 42 1992 631 639
17. W. Noble, D.P. Hanger, and J.M. Gallo Transgenic mouse models of tauopathy in drug discovery CNS Neurol Disord Drug Targets 9 2010 403 428
18. C.L. Vigen, W.J. Mack, R.S. Keefe, M. Sano, D.L. Sultzer, and T.S. Stroup Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: Outcomes from CATIE-AD Am J Psychiatry 168 2011 831 839
19. L.S. Schneider, K.S. Dagerman, and P. Insel Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials JAM 294 2005 1934 1943
20. L.S. Schneider, K. Dagerman, and P.S. Insel Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials Am J Geriatr Psychiatry 14 2006 191 210
21. H.M. Wisniewski, J. Constantinidis, J. Wegiel, M. Bobinski, and M. Tarnawski Neurofibrillary pathology in brains of elderly schizophrenics treated with neuroleptics Alzheimer Dis Assoc Disord 8 1994 211 227
22. R.B. Conolly Nonmonotonic dose-response relationships: Mechanistic basis, kinetic modeling, and implications for risk assessment Toxicol Sci 77 2004 151 157
23. S. Chiba, E. Takada, M. Tadokoro, T. Taniguchi, K. Kadoyama, and M. Takenokuchi Loss of dopaminoreceptive neuron causes L-dopa resistant parkinsonism in tauopathy Neurobiol Aging 33 2012 2491 2505
24. C.I. Bargmann Neurobiology of the Caenorhabditis elegans genome Science 282 1998 2028 2033